Trial Name:

COAST - Cisplatin Ototoxicity attenuated by ASpirin Trial

Description:

A placebo controlled study to gather initial information on whether aspirin reduces hearing loss/ototoxicity for patients receiving cisplatin chemotherapy.

Objectives:

Primary Objective:

• To establish whether aspirin can reduce hearing loss/ototoxicity for patients receiving cisplatin based chemotherapy.

Secondary Objectives:

• To determine whether it is feasible to conduct a Phase III randomised controlled Trial of aspirin for the same patient population.
• To quantify the extent of hearing loss in patients receiving cisplatin via the use of otoacoustic emissions (OAE).
• To determine whether patients are able to tolerate short-term, large doses of enteric-coated aspirin taken with omeprazole without significant side-effects and with no loss of cisplatin dose-intensity.

Design:

Randomised, Phase II, double-blind, placebo-controlled, two arm Trial.

Status:

Completed

Population:

39 patients over 18 years of age in each arm deemed fit for chemotherapy according to sites own local defined cancer network protocol for chemotherapy regimes.

Publications:

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss

Contact details:

All Trial enquiries should be addressed to ctu@soton.ac.uk